Wishlist (0)
Welcome visitor Login or Register.
My Cart    0 $0.00
Your shopping cart is empty!
ABT-263

ABT-263

0 reviews Write a review
Product Code: 3003
Availability: In Stock
$247.00
-+

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM, but binds more weakly to Mcl-1 and A1. Phase 1/2.

Chemical name: 

(R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide

Inhibitors Apoptosis Bcl-2 ABT-263 923564-51-6
Biological Activity:
Biological Activity ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM, but binds more weakly to Mcl-1 and A1. Phase 1/2.
Technical Data:
M.W. 974.61
Formula: <h1>&nbsp;C<sub>47</sub>H<sub>55</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>6</sub>S<sub>3</sub></h1>
Solubility: DMSO
Purity: 98%
Storage: -20℃
CAS No: 923564-51-6
References:
References Tse C, et al. Cancer Res. 2008, 68(9), 3421-3428. Shoemaker AR, et al. Clin Cancer Res, 2008, 14(11), 3268-3277.

Write a review

Note: HTML is not translated!
    Bad           Good
Continue

About HDH PHARMA

At HDH Pharma, we are committed to offering our clients the highest quality research services with the most convenient and effective communications from both US and Indian operations. Clients in the Americas and Europe can pick up the phone and speak directly with our scientists in the US. Clients in Asia can receive the same rapid response from our scientists in India. HDH’s hybrid operation is designed with our client’s operational needs in mind.


Information

Extras

My Account

Powered By Nsoft Solutions
HDH PHARMA © 2024